Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/8/2018
SIETES contiene 92466 citas

 
 
 1 a 20 de 14416 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Voelker R. Another caution for clarithromycin. JAMA 2018;319:1 de junio. [Ref.ID 102782]
2.Enlace a cita original Cita con resumen
Rothwell PPM, Cook PNR, Gaziano PJM, Price JF, Belch PJFF, Roncaglioni MC, Morimoto T, Mehta Z. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018:12 de julio. [Ref.ID 102745]
3.Enlace a cita original Cita con resumen
Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min YI, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med 2018;169:20-9. [Ref.ID 102647]
5.Enlace a cita original Cita con resumen
Park Y, Bateman BT, Kim DH, Hernandez-Diaz S, Patorno E, Glynn RJ, Mogun H, Hyubrechts KF. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. BMJ 2018;360:28 de marzo. [Ref.ID 102642]
6.Enlace a cita originalTiene citas relacionadas Cita con resumen
Tsourdi E, Rachner TD, Hofbauer LC. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102629]
7.Enlace a cita originalTiene citas relacionadas Cita con resumen
Lewis JR, Schousboe JT, Prince RL. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102628]
8.Enlace a cita originalTiene citas relacionadas Cita con resumen
Song GG, Lee YH. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102627]
9. Cita con resumen
Anónimo. Edoxaban: Interstitial lung disease. Japan . WHO Drug Information 2018;32:18. [Ref.ID 102620]
10.Enlace a cita original Cita con resumen
Malhotra K, Katsanos AH, Bilal M, Ishfaq MF, Goyal N, Tsivgoulis G. Cerebrovascular outcomes with proton pump inhibitors and thienopyridines. Stroke 2018;49:febrero. [Ref.ID 102619]
11.Enlace a cita original Cita con resumen
Pylypchuk R, Wells S, Kerr A, Poppe K, Riddell T, Harwood M, Exeter D, Mehta S, Grey C, Wu BP, Metcalf P, Warren J, Harrison J, Marshall R, Jackson R. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet 2018;391:12 de mayo. [Ref.ID 102612]
12.Enlace a cita original Cita con resumen
Chen TT, Yeh YC, Chien KL, Lai MS, Tu YK. Risk of infective endocarditis after invasive dental treatments: a case-only study. Circulation 2018:19 de abril. [Ref.ID 102607]
13.Enlace a cita original Cita con resumen
Kamali KN, Lloyd-Jones DM, van der Leeuw J, Goff Jr DC, Yusuf S, Zanchetti A, Glasziou P, Jackson R, Woodward M, Rodgers A, Neal BC, Berge E, Teo K, Davis BR, Chalmers J, Pepine C, Rahimi K, Sundström J, on behalf of the Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLOS Medicine 2018:20 de marzo. [Ref.ID 102591]
14. Cita con resumen
Anónimo. Nivolumab, pembrolizumab: cardiomyopathies. Prescrire 2018;38:188-9. [Ref.ID 102588]
15.Enlace a cita original Cita con resumen
Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Grossi CM, Mattishent K, Bennett K, Campbell NL, Boustani M, Robinson L, Brayne C, Matthews FE, Savva GM. Anticholinergic drugs and risk of dementia: case-control study. BMJ 2018;361:25 de abril. [Ref.ID 102571]
16.Enlace a cita original Cita con resumen
Bergman JEH, Lutke LR, Gans ROB, Addor M-C, Barisic I, Clavero-Carbonell C, Garne E, Gatt M, Klungsoyr K, Lelong N, Lynch C, Mokoroa O, Nelen V, Neville AJ, Pierini A, Randrianaivo H, Rißmann A, Tucker D, Wiesel A, Dolk H, Loane M, Bakker MK. Beta-blocker use in pregnancy and risk of specific congenital anomalies: A European case-malformed control study. Drug Saf 2018;41:415-27. [Ref.ID 102566]
18.Enlace a cita original Cita con resumen
Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, Ridefelt P, Lawrence JH, De Caterina R, Vinereanu D, Hanna M, Flaker G, Al-Khatib SM, Hohnloser SH, Alexander JH, Granger CB, Wallentin L, ARISTOTLE Committees and Investigators. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol 2018;71:13 de marzo. [Ref.ID 102547]
19.Enlace a cita original Cita con resumen
D'Silva M, Hallas J, Pottegård A, Kristiansen NS, Atsma WJ, Franks B, D'Silva M, Varas-Lorenzo C, Perez-Gutthann S, Arana J. Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study. Eur J Clin Pharmacol 2018;74:febrero. [Ref.ID 102545]
20.Enlace a cita original Cita con resumen
Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ 2018;360:6 de febrero. [Ref.ID 102541]
Seleccionar todas
 
 1 a 20 de 14416 siguiente >>